LLY

1,075.02

-0.2%↓

JNJ

206.37

+0.18%↑

ABBV

229.92

-0.17%↓

UNH

325.23

-0.03%↓

AZN

92.32

-0.3%↓

LLY

1,075.02

-0.2%↓

JNJ

206.37

+0.18%↑

ABBV

229.92

-0.17%↓

UNH

325.23

-0.03%↓

AZN

92.32

-0.3%↓

LLY

1,075.02

-0.2%↓

JNJ

206.37

+0.18%↑

ABBV

229.92

-0.17%↓

UNH

325.23

-0.03%↓

AZN

92.32

-0.3%↓

LLY

1,075.02

-0.2%↓

JNJ

206.37

+0.18%↑

ABBV

229.92

-0.17%↓

UNH

325.23

-0.03%↓

AZN

92.32

-0.3%↓

LLY

1,075.02

-0.2%↓

JNJ

206.37

+0.18%↑

ABBV

229.92

-0.17%↓

UNH

325.23

-0.03%↓

AZN

92.32

-0.3%↓

Начало・Списък с акции・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

4.32 2.13

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.22

Максимум

4.41

Ключови измерители
By Trading Economics
Приходи	9.6M -162M
Продажби	-14M 5.2M
EPS	-0.36
Марж на печалбата	-3,135.324
Служители	800
EBITDA	6.4M -141M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+76.14% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-81M 2.3B
Предишно отваряне	2.19
Предишно затваряне	4.32

Настроения в новините

By Acuity

50%

156 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

4.15 / 4.75 Подкрепа & съпротива

Recursion Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.12.2025 г., 15:21 ч. UTC

Печалби

Correction to Home Depot Outlook Headline on Dec. 9

23.12.2025 г., 23:54 ч. UTC

Пазарно говорене

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23.12.2025 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.12.2025 г., 21:21 ч. UTC

Придобивния, сливания и поглъщания

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23.12.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

St Barbara to Hold Deposit in Escrow

23.12.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23.12.2025 г., 21:19 ч. UTC

Придобивния, сливания и поглъщания

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23.12.2025 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23.12.2025 г., 20:16 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23.12.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23.12.2025 г., 19:13 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23.12.2025 г., 18:58 ч. UTC

Пазарно говорене

Gold Has Another Record-Setting Day -- Market Talk

23.12.2025 г., 18:32 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

23.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

23.12.2025 г., 17:09 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23.12.2025 г., 16:21 ч. UTC

Пазарно говорене

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23.12.2025 г., 16:16 ч. UTC

Пазарно говорене

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23.12.2025 г., 16:15 ч. UTC

Пазарно говорене

Precious Metals Pare Gains -- Market Talk

23.12.2025 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Bank: Closing Expected Around Mid-January

23.12.2025 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23.12.2025 г., 16:02 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23.12.2025 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Bank Receives Green Light for Acquisition in Poland

23.12.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23.12.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Telefonica Doesn't Set Out Financial Details of Divestment

23.12.2025 г., 15:41 ч. UTC

Придобивния, сливания и поглъщания

Telefonica: Deal Will Allow Focus on Core Markets

23.12.2025 г., 15:40 ч. UTC

Придобивния, сливания и поглъщания

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23.12.2025 г., 15:19 ч. UTC

Пазарно говорене

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Recursion Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

76.14% нагоре

12-месечна прогноза

Среден 7.75 USD 76.14%

Висок 11 USD

Нисък 5 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Recursion Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Recursion Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.15 / 4.75Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

156 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.